乳腺癌分子分型在新辅助化疗疗效及预后预测中的作用
刘娜;马天江;支卫国
【期刊名称】《现代肿瘤医学》 【年(卷),期】2017(025)010
【摘要】Objective:To investigate the predictive role of breast cancer molecular subtype in the response and outcome of breast cancer patients treated with neoadjuvant chemotherapy.Methods:We collected the data of 236 patients with primary breast cancer treated with neoadjuvant chemotherapy in Luohe Central Hospital in this retrospective study.The patients were classified into 4 subtypes:Luminal A,Luminal B,Her-2 positive and triple-negative.The correlation between molecular subtypes and clinic pathologic factors,efficacy of neoadjuvant chemotherapy and 5-year survival were analyzed.Results:Among all 236 patients,107(45.3%) patients were Luminal A subtype,47(19.9%) were Luminal B subtype,27(11.4%) were Her-2 positive subtype and 55(23.3%) were triple-negative subtype.The pCR rates of Her-2 positive(25.9%) and triple-negative(30.9%) subtypes were higher than those of Luminal subtype(Luminal A 4.7% and Luminal B 8.5%),with significant difference(P<0.05).Despite initial chemosensitivity,the patients with Her-2 positive and triple-negative subtypes had worse 5-year disease-free survival(DFS) and 5-year overall survival(OS)(P<0.01) than those with Luminal subtypes in the whole population.The 5-year DFS and OS of